Goodwin Procter LLP
Three Embarcadero Center
28 th Floor
San Francisco, CA 94111
goodwinlaw.com
+1 415 733 6000
 
June 8, 2017
 
 
VIA EDGAR
 
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
 
Re:
Anthera Pharmaceuticals, Inc.
Request for Withdrawal Pursuant to Rule 477 of Post-Effective Amendment No. 1 to Form S-8 filed under form type POS AM (File No. 333-218420 )
 
Ladies and Gentlemen:
 
On behalf of Anthera Pharmaceuticals, Inc. (the “Company”), we hereby submit this letter to notify the Securities and Exchange Commission (the “SEC”) of an inadvertent EDGAR filing submission error. On June 5, 2017, the Company filed with the SEC (via EDGAR) Post-Effective Amendment No. 1 to Form S-8 (File No. 333-218420) under form type “POS AM” instead of “S-8 POS”. Pursuant to Rule 477 under the Securities Act of 1933, as amended, the Company hereby withdraws the Post-Effective Amendment No. 1 to Form S-8 filed on June 5, 2017. The Company intends to refile the Post-Effective Amendment No. 1 to Form S-8 under form type “S-8 POS” on or around June 8, 2017 to correct this error.
 
Thank you for your assistance with this matter. If you have any questions or comments concerning this request, please call me at (415) 733-6099.
 
Sincerely,
 
/s/ Bradley A. Bugdanowitz
Bradley A. Bugdanowitz
 
cc:
May Liu
Senior Vice President, Finance and Administration
(Principal Accounting and Financial Officer)
Anthera Pharmaceuticals, Inc.
 

 
 
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Anthera Pharmaceuticals (CE) Charts.
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Anthera Pharmaceuticals (CE) Charts.